Persisting challenges in the early detection of hepatocellular carcinoma.

IF 2.8 3区 医学 Q2 ONCOLOGY Expert Review of Anticancer Therapy Pub Date : 2025-02-24 DOI:10.1080/14737140.2025.2467184
Ashwini Arvind, Kennedy Redmon, Amit G Singal
{"title":"Persisting challenges in the early detection of hepatocellular carcinoma.","authors":"Ashwini Arvind, Kennedy Redmon, Amit G Singal","doi":"10.1080/14737140.2025.2467184","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Prognosis in patients with HCC is largely determined by stage at diagnosis, highlighting the importance of effective early detection strategies. HCC surveillance is associated with increased early detection and reduced HCC-related mortality and is currently recommended in patients with cirrhosis or chronic HBV infection.</p><p><strong>Areas covered: </strong>We performed a targeted literature review to identify limitations of current HCC surveillance practices and strategies for improvement.</p><p><strong>Expert opinion: </strong>Semi-annual ultrasound continues as the cornerstone modality for HCC surveillance but has limited sensitivity for detecting early-stage HCC, particularly in patients with obesity and non-viral etiologies. Although sensitivity for early-stage HCC can be improved by using ultrasound with alpha fetoprotein, this strategy misses over one-third of HCC at an early stage. Emerging imaging and biomarker-based surveillance strategies currently remain in varying stages of validation and are not yet ready for routine use in practice. The cost-effectiveness of surveillance in patients with non-cirrhotic liver disease related to hepatitis C or metabolic dysfunction-associated steatotic liver disease continues to be debated, although subgroups with advanced fibrosis may warrant surveillance. Finally, the effectiveness of surveillance is diminished by underuse in clinical practice, particularly in racial minority and low-income groups, highlighting a need for interventions to increase utilization.</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":2.8000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12353231/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2467184","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Prognosis in patients with HCC is largely determined by stage at diagnosis, highlighting the importance of effective early detection strategies. HCC surveillance is associated with increased early detection and reduced HCC-related mortality and is currently recommended in patients with cirrhosis or chronic HBV infection.

Areas covered: We performed a targeted literature review to identify limitations of current HCC surveillance practices and strategies for improvement.

Expert opinion: Semi-annual ultrasound continues as the cornerstone modality for HCC surveillance but has limited sensitivity for detecting early-stage HCC, particularly in patients with obesity and non-viral etiologies. Although sensitivity for early-stage HCC can be improved by using ultrasound with alpha fetoprotein, this strategy misses over one-third of HCC at an early stage. Emerging imaging and biomarker-based surveillance strategies currently remain in varying stages of validation and are not yet ready for routine use in practice. The cost-effectiveness of surveillance in patients with non-cirrhotic liver disease related to hepatitis C or metabolic dysfunction-associated steatotic liver disease continues to be debated, although subgroups with advanced fibrosis may warrant surveillance. Finally, the effectiveness of surveillance is diminished by underuse in clinical practice, particularly in racial minority and low-income groups, highlighting a need for interventions to increase utilization.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肝细胞癌早期发现的持续挑战。
HCC患者的预后在很大程度上取决于诊断阶段,这突出了有效的早期发现策略的重要性。HCC监测与增加早期发现和降低HCC相关死亡率相关,目前推荐用于肝硬化或慢性HBV感染患者。涵盖领域:我们进行了一项有针对性的文献综述,以确定当前HCC监测实践的局限性和改进策略。专家意见:半年一次的超声检查仍然是HCC监测的基础方式,但对早期HCC的检测灵敏度有限,特别是对肥胖和非病毒性病因的患者。虽然早期HCC的敏感性可以通过使用超声和甲胎蛋白来提高,但这种策略在早期错过了超过三分之一的HCC。新兴的成像和基于生物标志物的监测策略目前仍处于不同的验证阶段,尚未准备好在实践中常规使用。监测与丙型肝炎相关的非肝硬化肝病或代谢功能障碍相关的脂肪变性肝病患者的成本效益仍存在争议,尽管晚期纤维化亚组可能需要监测。最后,在临床实践中,特别是在少数种族和低收入群体中,监测的有效性因使用不足而降低,突出表明需要采取干预措施以提高利用率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.10
自引率
3.00%
发文量
100
审稿时长
4-8 weeks
期刊介绍: Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.
期刊最新文献
A systematic review on clinical pharmacokinetics and pharmacodynamics of antiangiogenic tyrosine kinase inhibitors (TKIs) with high TDM scores. Clinical management of oligoprogressive renal cell carcinoma. Determinants of survival after neoadjuvant chemotherapy in resectable gastric cancer: adjuvant dose intensity, radiotherapy, and pathologic response. National Delphi consensus on perioperative and locally advanced NSCLC management in Colombia. Post-CDK4/6 inhibitor treatment landscape in metastatic hormone receptor-positive breast cancer: a narrative review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1